Delivery Order 36F79719D0224-36C24525N0224
Award Date
12/9/24
Potential Completion Date
12/11/24
Potential Value
$37K
Federal Agency
Veterans Integrated Service Network 5
Awardee
Horizon Therapeutics Usa, Inc.
Ultimate Awardee
Not listed
NAICS Category
325412 - Pharmaceutical Preparation Manufacturing
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
La Vergne, TN 37086, USA
Solicitation Procedures
Multiple Award, Fair Opportunity
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a $93,172.20 firm fixed-price delivery order awarded by the Department of Veterans Affairs (VA) to Horizon Therapeutics USA, Inc. for the drug KRYSTEXXA 8MG. The order was placed against Horizon's $25 million Multiple Award Schedule contract for Pharmaceuticals and Drugs (FSS-61-IB) with the VA, which has an expiration date of August 2025. Horizon also holds an $18 million Blanket Purchase Agreement (BPA) against the same Pharmaceuticals and Drugs Schedule, covering the procurement of...
This delivery order for $55,903.32 was awarded by the Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 5 to Horizon Therapeutics USA Inc. against the company's Multiple Award Schedule contract for Pharmaceuticals and Drugs (FSS-61-IB). The firm fixed price order, with no set-aside designation, is for the medication KRYSTEXXA 8MG and aims to supply VHA hospitals and clinics in La Vergne, Tennessee with this orphan disease treatment through...
This federal contract award is for the delivery of KRYSTEXXA 8MG, a specialty pharmaceutical product, to the U.S. Department of Veterans Affairs (VA). The contract was awarded to Horizon Therapeutics USA, Inc., a global biotechnology company that specializes in rare, autoimmune, and inflammatory disease treatments. The $74,667.32 firm fixed-price delivery order was placed against Horizon's existing Pharmaceuticals and Drugs (FSS-61-IB) Multiple Award Schedule contract with the General Services...
The U.S. Department of Veterans Affairs (VA) awarded a $76,896.72 firm fixed-price delivery order to Horizon Therapeutics USA, Inc. for the specialty pharmaceutical KRYSTEXXA 8MG. The award is part of Horizon's Federal Supply Schedule (FSS) contract for Pharmaceuticals and Drugs (FSS-61-IB) and is placed by the VA's Veterans Integrated Service Network (VISN) 5. This delivery order supports the VA's mission to provide comprehensive healthcare services to the veteran population, as KRYSTEXXA is...
The Department of Veterans Affairs (VA) Veterans Health Administration (VHA) awarded a firm fixed-price delivery order to Horizon Therapeutics USA, Inc. for the specialty pharmaceutical KRYSTEXXA 8MG. The $55,903.32 order is placed against Horizon's existing General Services Administration (GSA) Multiple Award Schedule (MAS) contract for Pharmaceuticals and Drugs (FSS-61-IB). This delivery order will provide the VA with pegloticase injections to treat chronic gout in eligible veterans through...
The Department of Veterans Affairs (VA) Veterans Health Administration (VHA) awarded a Delivery Order to Horizon Therapeutics USA Inc. for the specialty pharmaceutical KRYSTEXXA 8MG. The contract, with a potential value of $55,903.32, is a Firm Fixed Price order placed against Horizon Therapeutics' Federal Supply Schedule (FSS) contract for Pharmaceuticals and Drugs (FSS-61-IB). The Delivery Order has an April 17, 2024 completion date and does not have a set-aside designation. Horizon...
This contract award is for the delivery of KRYSTEXXA 8MG, a specialty pharmaceutical product, to the United States Department of Veterans Affairs (VA). The contract, valued at $37,268.88, is a firm fixed-price delivery order placed by the VA's Veterans Integrated Service Network 5 (VISN 5) against the prime contractor Horizon Therapeutics USA, Inc.'s Federal Supply Schedule (FSS) contract for Pharmaceuticals and Drugs (FSS-61-IB). Horizon Therapeutics USA, Inc. is a global biotechnology...
This is a delivery order awarded by the Department of Veterans Affairs (VA) Veterans Health Administration (VHA) to Horizon Therapeutics USA Inc. for the drug KRYSTEXXA 8MG/ML VIAL. The order is placed against Horizon's pre-existing General Services Administration (GSA) Multiple Award Schedule (MAS) contract for Pharmaceuticals and Drugs (FSS-61-IB). The order has a firm fixed price of $74,537.76 and a completion date of May 31, 2024. Horizon Therapeutics USA Inc. is a global biotechnology...
The Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 5 awarded Horizon Therapeutics USA Inc. a firm fixed price delivery order valued at fifty-three thousand nine hundred thirteen dollars and eighty-seven cents ($53,913.87) to provide KRYSTEXXA 8MG. The order was placed against Horizon's Pharmaceuticals and Drugs schedule contract with the General Services Administration. Performance will occur in La Vergne, Tennessee over a period of two days...
Horizon Therapeutics USA Inc. has been awarded a delivery order against the Pharmaceuticals and Drugs Federal Supply Schedule by the Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 5. The $16,558.72 firm fixed price order is for the drug KRYSTEXXA 8MG and has a period of performance through February 1, 2022. No set-aside designation was used for this order placed under GSA Schedule contract FSS-61-IB to supply pharmaceutical products and drugs to...